Page 2 - Beckley Psytech News Today

In an exciting collaboration, modern mental health company, Clerkenwell Health, and Beckley Psytech, a clinical-stage biotechnology company, have launched a phase 2a study aimed at investigating a potential breakthrough treatment for alcohol use disorder (AUD).

NOVEL PSYCHEDELIC COMPOUND TO BE TESTED FOR TREATMENT OF ALCOHOL USE DISORDER Novel psychedelic compound, combined with psychological support, will be explored as a potential new treatment for people living with alcohol use disorder (AUD).The trial uses Beckley Psytech’s lead candidate BPL-003, a short-du...

27.03.2024 - - A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12 - 55% of patients achieved a clinical response on the day after dosing and this rate of ... Seite 1

The short-acting psychedelic, BPL-003, resulted in rapid, durable depression symptom reduction in patients with TRD.

Venture Capital firm, Negev Capital, holds a portfolio of companies creating neuropsychiatric drugs based on psychedelic molecules.

Some forms of depression cannot be cured by current treatments including antidepressants or going to psychological counselling or psychotherapy.

About 43.8 million adults in the U.S. experience a mental health issue in a given year, according to the National Institute of Mental Health (NAMI). Nearly 16 million of those adults live with major depression. Another 18.1% live with anxiety disorders. ...

About 43.8 million adults in the U.S. experience a mental health issue in a given year, according to the National Institute of Mental Health (NAMI). Nearly 16 million of those adults live with major depression. Another 18.1% live with anxiety disorders. ...

At the moment, about 14 million people live with PTSD just in the U.S. Unfortunately, despite extensive clinical research, PTSD is still a significant unmet medical need. However, that may soon change with the US FDA’s acceptance of a New Drug ...